A Novel Antibody-Drug Conjugate for Targeting Tumor-Associated Macrophages in Solid Tumors

Introduction

The project is focused on the development of a groundbreaking Antibody-Drug Conjugate (ADC) specifically designed for macrophage depletion in the Tumor Microenvironment (TME). With a primary focus on breast cancer and solid tumors, this initiative represents a paradigm shift in cancer therapeutics.

Background

The presence of Tumor-Associated Macrophages (TAMs) in the TME has been identified as a significant factor in tumor progression and immune evasion. Our proposed ADC will directly target these macrophages, effectively depleting them and thereby creating a more favorable environment for tumor eradication.

Objectives

The primary objectives of this project are as follows:

1. To synthesize and optimize ADCs for specific targeting and depletion of TAMs in the TME.
2. To demonstrate the efficacy of the ADC in preclinical models, establishing its potential for human application.
3. To perform a thorough "freedom to operate" analysis, ensuring that the ADC technology does not infringe upon existing intellectual property rights.
4. To establish a detailed plan for the commercial development of this ADC, outlining steps for regulatory approval, manufacturing scalability, and market entry.

Impact

By achieving these objectives, we aim to propel this project from the conceptual stage to a viable, commercializable medical solution. The successful implementation of this ADC has the potential to revolutionize cancer treatment, offering a targeted approach that could significantly improve patient outcomes.

Funding

The support of the ERC Proof of Concept Grant will be pivotal in transitioning this transformative technology from the laboratory to the marketplace, ultimately changing the landscape of cancer therapeutics.

Institutional Support

The strategic positioning of Zelula Biopharma (Host Institution) as a spin-off of CIC bioGUNE adds substantial value to this project, leveraging a unique blend of resources, academic research excellence, and entrepreneurial agility to accelerate the transition from lab to market.